Your browser is no longer supported. Please, upgrade your browser.
EXEL Exelixis, Inc. daily Stock Chart
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own0.20% Shs Outstand272.44M Perf Week8.13%
Market Cap4.86B Forward P/E- EPS next Y-0.02 Insider Trans-50.57% Shs Float260.85M Perf Month74.80%
Income-149.00M PEG- EPS next Q-0.01 Inst Own77.20% Short Float6.99% Perf Quarter47.60%
Sales123.80M P/S39.24 EPS this Y41.30% Inst Trans15.91% Short Ratio2.64 Perf Half Y150.42%
Book/sh0.12 P/B148.58 EPS next Y95.90% ROA-36.00% Target Price18.50 Perf Year230.19%
Cash/sh1.17 P/C15.19 EPS next 5Y- ROE160.90% 52W Range3.55 - 17.74 Perf YTD216.13%
Dividend- P/FCF17.62 EPS past 5Y0.90% ROI-43.80% 52W High0.51% Beta1.81
Dividend %- Quick Ratio2.10 Sales past 5Y-27.50% Gross Margin95.40% 52W Low402.25% ATR0.88
Employees115 Current Ratio2.10 Sales Q/Q528.30% Oper. Margin- RSI (14)69.03 Volatility4.76% 6.19%
OptionableYes Debt/Eq5.97 EPS Q/Q79.00% Profit Margin- Rel Volume0.83 Prev Close17.37
ShortableYes LT Debt/Eq2.55 EarningsNov 03 AMC Payout- Avg Volume6.92M Price17.83
Recom1.50 SMA2011.87% SMA5030.36% SMA200101.44% Volume5,534,600 Change2.65%
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Dec-05-16 06:11PM  This Dynamic Duo of Catalysts Sent Exelixis, Inc. Higher by 60% in November at Motley Fool
03:15AM  Hedge Funds Arent Crazy About John Bean Technologies Corp (JBT) Anymore at Insider Monkey
Dec-02-16 01:03PM  Why Exelixis Was a Top Stock in 2016 So Far at Motley Fool +5.15%
09:21AM  3 Biotech Stocks to Buy in December at Motley Fool
Dec-01-16 04:20PM  5 Top Performing Biotechnology Stocks of November
11:08AM  Exelixis (EXEL): Strong Industry, Solid Earnings Estimate Revisions
Nov-30-16 07:43PM  5 Stocks Up 100% or More This Year at Motley Fool
05:36PM  Is Wright Medical Group Inc (WMGI) a Good Stock for Your Portfolio? at Insider Monkey
04:41PM  What's Pfizer's Excuse for Not Buying Exelixis? at Motley Fool
04:15PM  Exelixis to Present at the BMO Prescription for Success Healthcare Conference on December 14 Business Wire
10:40AM  Hedge Funds Are Buying RealPage, Inc. (RP) at Insider Monkey
10:02AM  The 5 Best Biotech Stocks of 2016 at Motley Fool
09:46AM  Should You Buy Exelixis, Inc. (EXEL)? at Insider Monkey
Nov-29-16 01:52PM  Shark Bites: Eager Buyers Pounce on Pullback
Nov-28-16 07:32PM  3 Healthcare Stocks Investors Have Been Thankful for This Year at Motley Fool
Nov-24-16 05:48PM  The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3 at Insider Monkey
Nov-23-16 09:30AM  4 stocks to watch at MarketWatch
Nov-22-16 05:09PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -5.36%
01:49PM  How to Be a Smarter Biotech Investor
08:54AM  Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults
Nov-21-16 04:17PM  Exelixis to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 29 Business Wire
Nov-18-16 04:40PM  Is Exelixis the Best Small-Cap Biotech Stock? at Motley Fool
09:30AM  New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day
08:48AM  Endo Reports Positive Cellulite Treatment Data on Xiaflex
Nov-17-16 09:29AM  3 Things Exelixis Must Do to Survive and Thrive in 2017 at Motley Fool
08:56AM  3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise
08:17AM  Bristol-Myers, Enterome Ink Immuno-Oncology Collaboration
Nov-16-16 10:27AM  Surging Earnings Estimates Signal Good News for Exelixis (EXEL)
08:20AM  Pfizer Reports Phase III Psoriatic Arthritis Data on Xeljanz
Nov-15-16 08:03AM  Celldex Stock Up on Positive Data on New Cancer Candidate
07:39AM  Repros (RPRX) Reports Positive Top-Line Data on Proellex
Nov-14-16 08:35AM  Alexion (ALXN) Offers Long-Term Phase III Data on Kanuma
08:04AM  Gilead (GILD) HBV Drug Vemlidy Gets Positive CHMP Opinion
Nov-12-16 12:16PM  Election 2016's Healthcare Winners and Losers at Motley Fool
Nov-11-16 02:51PM  VIVUS (VVUS) Reports Narrower-than-Expected Loss in Q3
01:04PM  EXELIXIS, INC. Financials
09:30AM  The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte
Nov-10-16 08:09AM  Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q3
Nov-09-16 02:25PM  Why These Biotechs Saw Double-Digit Gains Today at Motley Fool +20.45%
Nov-08-16 12:02PM  ETFs with exposure to Exelixis, Inc. : November 8, 2016
11:06AM  2 Reasons Exelixis, Inc. Dove 17% in October, and 1 Excuse to Be Excited at Motley Fool
10:07AM  PerkinElmer (PKI) Beats on Earnings, Misses Revenue in Q3
08:54AM  Wright Medical (WMGI) Q3 Loss Narrower than Expected
07:57AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : November 8, 2016
Nov-07-16 04:08PM  Exelixis, Inc. Continues Its Solid Launch at Motley Fool
04:05PM  Exelixis to Present at the Stifel 2016 Healthcare Conference on November 15 Business Wire
09:50AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016
08:21AM  Pacific Biosciences (PACB) Q3 Loss Narrower than Expected
01:00AM  Exelixis Announces Presentation of Cobimetinib Combination Therapy Data at the Society for Melanoma Research 2016 Congress That Support Genentechs Planned Phase 3 Pivotal Trials Business Wire
Nov-05-16 12:01PM  Why We're Excited About These 5 Top Stocks at Motley Fool
Nov-04-16 04:37PM  Exelixis (EXEL) Q3 Loss Narrower than Expected, Sales Beat +16.76%
03:12PM  Exelixis (EXEL) Stock Gains on Q3 Results
02:48PM  Why Exelixis, Inc. Reported Higher Today at Motley Fool
09:35AM  Intercept (ICPT) Q3 Loss Narrower than Expected, Sales Miss
09:32AM  Aegerion (AEGR) Reports Narrower-than-Expected Loss in Q3
Nov-03-16 07:10PM  Edited Transcript of EXEL earnings conference call or presentation 3-Nov-16 9:00pm GMT -5.64%
06:50PM  Exelixis reports 3Q loss
04:13PM  EXELIXIS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:07PM  Exelixis Announces Third Quarter and Year to Date 2016 Financial Results and Provides Corporate Update Business Wire
04:06PM  EXELIXIS, INC. Files SEC form 10-Q, Quarterly Report
03:25PM  Coverage initiated on Exelixis by Deutsche Bank
11:08AM  Aerie (AERI) Q3 Loss Wider than Expected, Pipeline in Focus
09:00AM  Alkermes (ALKS) Q3 Loss in Line, Sales Miss; '16 View Intact
07:07AM  Q3 2016 Exelixis Inc Earnings Release - After Market Close
Nov-02-16 02:37PM  4 stocks to watch at MarketWatch
01:25PM  Four Medical And Biotech Stock Charts To Watch at Forbes
10:48AM  AmerisourceBergen (ABC) Q4 Earnings Top, Revenues Lag
08:14AM  Prothena (PRTA) Reports Wider-than-Expected Loss in Q3
08:13AM  Shire (SHPG) Misses Q3 Earnings & Revenue Estimates
08:03AM  Drug Stocks Q3 Earnings Roster for Nov 3; ICPT, EXEL, AKRX
Oct-31-16 11:38AM  Novo Nordisk (NVO) Tops Q3 Earnings, Revenues Up Y/Y
10:16AM  ImmunoGen (IMGN) Reports Wider-than-Expected Loss
09:22AM  Exelixis (EXEL) Q3 Earnings: What's in Store for the Stock?
Oct-28-16 11:23AM  AbbVie (ABBV) Q3 Earnings in Line, Revenues Lag Estimates
09:35AM  Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3
08:24AM  McKesson (MCK) Misses on Q2 Earnings & Sales, Cuts View
Oct-27-16 11:45AM  Celgene (CELG) Beats on Q3 Earnings, Raises '16 Outlook
10:33AM  The Medicines Co. (MDCO) Q3 Loss Narrower than Expected
Oct-26-16 09:30AM featured highlights: Incyte, LegacyTexas Financial Group, Exelixis, Bayerische Motoren Werke Aktiengesellschaft and EQT Midstream Partners
09:17AM  Express Scripts (ESRX) Q3 Earnings in Line, Revenues Lag
Oct-25-16 04:32PM  Ligand Partner Melinta Therapeutics Submits NDA for Baxdela
10:04AM  Merck (MRK) Beats on Q3 Earnings & Revenues, Lifts View
09:48AM  5 Profitable Stocks for Outstanding Returns
09:27AM  Aduro Stock Down on Partial Clinical Hold on LADD Studies
07:54AM  What's in Store for Merit Medical (MMSI) in Q3 Earnings?
Oct-24-16 04:19PM  C.R. Bard (BCR) to Report Q3 Earnings: What's in the Cards?
11:04AM  Can Nutrisystem (NTRI) Surprise Investors in Q3 Earnings?
09:35AM  Merck Gets FDA Approval for Investigational Drug Zinplava
Oct-21-16 10:00AM  Amgen's (AMGN) Xgeva Meets Endpoint in Phase III Study
Oct-20-16 04:21PM  Exelixis to Release Third Quarter 2016 Financial Results on Thursday, November 3, 2016 Business Wire
03:52PM  41 Billion Reasons Why Gilead Sciences Might Need New Management at Motley Fool
09:58AM  Merck's Antiviral Medicine Meets Endpoint in Phase III
07:51AM  Eli Lilly Lartruvo Gets FDA Approval for Soft Tissue Sarcoma
Oct-19-16 09:56AM  AstraZeneca's Hyperkalemia Drug NDA Resubmission Accepted
07:55AM  Shire Cancer Drug Onivyde Receives EU Marketing Approval
Oct-18-16 10:05AM  J&J (JNJ) Outshines in Q3 Earnings on Strong Pharma Sales
09:23AM  Teva Trisenox Wins CHMP Nod for Expanded Use in Leukemia
09:23AM  Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status CNW Group
08:59AM  PTC Therapeutics Falls on FDA Denial of DMD Drug Appeal
Oct-17-16 09:14AM  Allergan (AGN) Gains Rights to RTGel from UroGen Pharma
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. The company has received regulatory approval for two separate formulations of cabozantinib for the treatment of certain forms of kidney and thyroid cancer and marketed as CABOMETYX tablets in the United States and COMETRIQ capsules in the United States and European Union respectively. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in the United States and European Union; and is being evaluated for further potential indications by Roche and Genentech under collaboration with Exelixis. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Option Exercise8.9922,000197,780180,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Option Exercise5.2770,000368,800143,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Sale16.7322,000368,060158,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Sale16.6670,0001,166,20073,600Dec 02 07:14 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Option Exercise5.1770,000362,000143,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Option Exercise8.9922,000197,780180,053Nov 14 07:36 PM
MORRISSEY MICHAELPresident and CEONov 09Option Exercise8.99200,0001,798,000260,000Nov 14 07:37 PM
MORRISSEY MICHAELPresident and CEONov 09Sale15.00200,0003,000,00060,000Nov 14 07:37 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Sale15.0022,000330,000158,053Nov 14 07:36 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Sale13.1570,000920,50073,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Option Exercise9.73132,6621,290,801267,596Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Sale10.98131,1551,440,082136,441Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Option Exercise9.7342,338411,949174,354Aug 05 07:29 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Sale11.0042,338465,718132,016Aug 05 07:29 PM
Hessekiel JeffreyEVP and General CounselJun 01Option Exercise1.70200,000340,000230,367Jun 02 06:37 PM
WILLSEY LANCEDirectorMay 11Buy4.9520,00099,000568,273May 11 05:23 PM
WILLSEY LANCEDirectorMay 09Buy4.9740,000198,900548,273May 11 05:23 PM
WILLSEY LANCEDirectorDec 11Buy4.7850,000239,000494,975Dec 11 07:43 PM
WILLSEY LANCEDirectorDec 10Buy4.9950,000249,550444,975Dec 11 07:43 PM